Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - aspirin,clopidogrel hydrogen sulfate -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - aspirin,clopidogrel hydrogen sulfate -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - aspirin,dipyridamole -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - aspirin, quantity: 100 mg; clopidogrel hydrogen sulfate, quantity: 97.87 mg (equivalent: clopidogrel, qty 75 mg) - tablet - excipient ingredients: crospovidone; glycerol dibehenate; lactose; hydrogenated castor oil; microcrystalline cellulose; colour - clopidogrel/aspirin is a fixed-dose combination product.,clopidogrel/aspirin is intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel/aspirin is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent); st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel/aspirin has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - aspirin, quantity: 100 mg; clopidogrel hydrogen sulfate, quantity: 97.87 mg (equivalent: clopidogrel, qty 75 mg) - tablet - excipient ingredients: lactose; microcrystalline cellulose; crospovidone; hydrogenated castor oil; glycerol dibehenate; colour - clopidogrel/aspirin is a fixed-dose combination product.,clopidogrel/aspirin is intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel/aspirin is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent); st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel/aspirin has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - aspirin, quantity: 100 mg; clopidogrel hydrogen sulfate, quantity: 97.87 mg (equivalent: clopidogrel, qty 75 mg) - tablet - excipient ingredients: lactose; crospovidone; glycerol dibehenate; hydrogenated castor oil; microcrystalline cellulose; colour - clopidogrel/aspirin is a fixed-dose combination product.,clopidogrel/aspirin is intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel/aspirin is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent); st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel/aspirin has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

ABD - İngilizce - NLM (National Library of Medicine)

padagis us llc - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e) - aspirin 300 mg - for the relief of minor aches, pains and headache and for reduction of fever.

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

bayer limited - aspirin - effervescent tablet - 300 milligram(s) - salicylic acid and derivatives; acetylsalicylic acid

ABD - İngilizce - NLM (National Library of Medicine)

avkare - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), dipyridamole (unii: 64alc7f90c) (dipyridamole - unii:64alc7f90c) - aspirin 25 mg - aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. aspirin and extended-release dipyridamole capsules are contraindicated in patients with known hypersensitivity to any of the product components. aspirin, usp is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drug (nsaid) products and in patients with the syndrome of asthma, rhinitis and nasal polyps. aspirin, usp may cause severe urticaria, angioedema or bronchospasm. do not use aspirin, usp in children or teenagers with viral infections because of the risk of reye syndrome. teratogenic effects, pregnancy category d. [see warnings and precautions (5.4)]. aspirin can result in excessive blood loss at delivery as well as prolonged gestation and prolonged labor. because of these effects on the mother and because of adverse fetal effects seen with aspirin during the later stages of pregnancy [see warnings and precautions (5.4)] , avoid aspirin and extended-release dipyridamole in the third trimester of pregnancy and during labor and delivery. both dipyridamole and aspirin are excreted in human milk. exercise caution when aspirin and extended-release dipyridamole capsules are administered to a nursing woman. safety and effectiveness of aspirin and extended-release dipyridamole in pediatric patients have not been studied. due to the aspirin component, use of this product in the pediatric population is not recommended [see contraindications (4.3)] . of the total number of subjects in esps2, 61 percent were 65 and over, while 27 percent were 75 and over. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see clinical pharmacology (12.3)] . aspirin and extended-release dipyridamole has not been studied in patients with hepatic or renal impairment. avoid using aspirin containing products, such as aspirin and extended-release dipyridamole in patients with severe hepatic or severe renal (glomerular filtration rate < 10 ml/min) dysfunction [see  warnings and precautions (5.2,  5.3) and clinical pharmacology (12.3)] .

ABD - İngilizce - NLM (National Library of Medicine)

american health packaging - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), dipyridamole (unii: 64alc7f90c) (dipyridamole - unii:64alc7f90c) - aspirin 25 mg - aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. aspirin and extended-release dipyridamole capsules are contraindicated in patients with known hypersensitivity to any of the product components. aspirin, usp is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drug (nsaid) products and in patients with the syndrome of asthma, rhinitis and nasal polyps. aspirin, usp may cause severe urticaria, angioedema or bronchospasm. do not use aspirin, usp in children or teenagers with viral infections because of the risk of reye syndrome. teratogenic effects, pregnancy category d. [see warnings and precautions (5.4)]. aspirin can result in excessive blood loss at delivery as well as prolonged gestation and prolonged labor. because of these effects on the mother and because of adverse fetal effects seen with aspirin during the later stages of pr